CAR-T in, IPF drug out: Galapagos bails on biotech partnership amid pipeline revamp
It turns out that Paul Stoffels’ new plans for Galapagos don’t just involve buying new things. The Johnson & Johnson R&D vet — and new biotech CEO — is also clearing out the attic.
Galapagos is returning rights to a dual chitinase inhibitor it had licensed back in 2020 from Molecure, a Warsaw, Poland-based small molecule drug developer then known as OncoArendi, for €25 million upfront.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.